文献速递外周动脉疾病

血管内碎石术治疗股总动脉闭塞性疾病

Intravascular Lithotripsy for Common Femoral Artery Occlusive Disease.
PubMed 文献 · Ann Vasc Surg · 2024-12-12

本研究分析2021年9月至2023年4月因慢性肢体威胁性缺血接受股总动脉血管内碎石术(IVL)治疗的患者,评估其安全性与可行性。共纳入15例患者,技术成功率为100%,IVL后平均残余狭窄为11.88%(标准差6.8),随访期间临床驱动的靶病变血运重建累积发生率为0%。作者认为IVL联合药物涂层球囊(DCB)血管成形术安全可行,早期结果令人鼓舞,但需长期随访研究证实。

要点

  • 15例慢性肢体威胁性缺血患者接受股总动脉IVL治疗,技术成功率为100%。
  • IVL后平均残余狭窄为11.88%(标准差6.8),无需支架置入。
  • 随访期间临床驱动的靶病变血运重建累积发生率为0%,1例发生肾功能恶化相关主要不良事件。

核心结论

  • IVL联合DCB血管成形术是治疗慢性肢体威胁性缺血患者股总动脉病变的安全可行技术,与文献所述开放手术系列相比发病率和死亡率更低。
  • 作者认为IVL可能成为开放手术的良好替代方案,但这些令人鼓舞的早期结果必须通过长期随访研究证实。

研究设计与样本

  • 本研究分析2021年9月至2023年4月接受股总动脉IVL治疗的患者,所有患者均表现为慢性肢体威胁性缺血。
  • 标准手术方式为IVL联合辅助性DCB血管成形术,使用紫杉醇或西罗莫司涂层球囊。
  • 主要终点为评估IVL对股总动脉粥样硬化病变的有效性,次要终点包括主要不良事件和临床驱动的靶病变血运重建。

主要发现

  • 共纳入15例患者,除1例外均接受IVL联合DCB血管成形术。
  • 技术成功率为100%,IVL后平均残余狭窄为11.88%(标准差6.8),无需支架置入。
  • 14例患者接受辅助性DCB血管成形术,其中4例使用紫杉醇涂层球囊,10例使用西罗莫司涂层球囊。
  • 记录到1例主要不良事件,为既往慢性肾脏病患者肾功能恶化。
  • 术后期间3例患者死亡,其余11例患者平均随访时间为14个月(标准差5.68);Rutherford分级平均改善3.58(标准差0.79),随访期间临床驱动的靶病变血运重建累积发生率为0%。

临床怎么用

  • 作者认为IVL联合DCB血管成形术是治疗慢性肢体威胁性缺血患者股总动脉病变的安全可行技术,可能成为开放手术的良好替代方案。
  • 作者指出这些令人鼓舞的早期结果必须通过长期随访研究证实。

局限性

  • 作者指出这些令人鼓舞的早期结果必须通过长期随访研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study is to assess the safety and feasibility of intravascular lithotripsy (IVL) for the treatment of the common femoral artery (CFA). METHODS: We analyzed patients who received IVL treatment for CFA from September 2021 to April 2023. All patients included presented with chronic limb-threatening ischemia. Standard procedure was IVL with adjunctive drug-coated balloon (DCB) angioplasty using either Paclitaxel or Sirolimus. Primary endpoint was to assess effectiveness of IVL for atherosclerotic common femoral lesions. Secondary endpoints include major adverse events and clinically driven target lesion revascularization. RESULTS: A total of 15 patients were included in the study. All but 1 received IVL + DCB angioplasty. Technical success was 100% with a mean residual stenosis after IVL of 11.88% (standard deviation [SD] 6.8). No scaffolding was needed. Adjunctive DCB angioplasty was used in 14 patients, 4 of them with a Paclitaxel-coated balloon and Sirolimus-coated balloon in the other 10 patients. One major adverse event was registered due to worsening of renal function in a patient with previous chronic kidney disease. Three patients died during the postoperative period, and for the other 11 patients, the mean follow-up was 14 months (SD 5.68). Mean upgrade in Rutherford Class was 3.58 (SD 0.79) and cumulative clinically driven target lesion revascularization during follow-up was 0%. CONCLUSIONS: IVL with adjunctive DCB angioplasty is a safe and feasible technique for treating CFA in chronic limb-threatening ischemia patients, with lower morbidity and mortality rates compared with open surgical series described in the literature. This implies shorter hospital stay and a faster recovery. IVL may be a good alternative to open surgery, but these encouraging early results must be confirmed with long-term follow-up studies.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Del Canto Peruyera P, Linares Sánchez M, Álvarez Salgado A, et al. Intravascular Lithotripsy for Common Femoral Artery Occlusive Disease. Ann Vasc Surg. 2024. PMID: 39672266. doi:10.1016/j.avsg.2024.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。